These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 20870626

  • 1. The effects of three alternative treatment strategies after 8 weeks of proton pump inhibitor therapy for GERD in children.
    Lee JH, Kim MJ, Lee JS, Choe YH.
    Arch Dis Child; 2011 Jan; 96(1):9-13. PubMed ID: 20870626
    [Abstract] [Full Text] [Related]

  • 2. Dexlansoprazole (Kapidex) for GERD and erosive esophagitis.
    Med Lett Drugs Ther; 2009 Mar 23; 51(1308):21-2. PubMed ID: 19305367
    [No Abstract] [Full Text] [Related]

  • 3. [Diagnosis and therapy of gastroesophageal reflux disease with lansoprazole].
    Bordin DS, Masharova AA.
    Eksp Klin Gastroenterol; 2008 Mar 23; (5):85-90. PubMed ID: 19145922
    [No Abstract] [Full Text] [Related]

  • 4. Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis.
    Fock KM, Ang TL.
    Curr Opin Investig Drugs; 2008 Oct 23; 9(10):1108-15. PubMed ID: 18821474
    [Abstract] [Full Text] [Related]

  • 5. Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis.
    Baker R, Tsou VM, Tung J, Baker SS, Li H, Wang W, Rath N, Maguire MK, Comer GM.
    Clin Pediatr (Phila); 2010 Sep 23; 49(9):852-65. PubMed ID: 20522615
    [Abstract] [Full Text] [Related]

  • 6. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
    Fass R, Johnson DA, Orr WC, Han C, Mody R, Stern KN, Pilmer BL, Perez MC.
    Am J Gastroenterol; 2011 Mar 23; 106(3):421-31. PubMed ID: 21224838
    [Abstract] [Full Text] [Related]

  • 7. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
    Emerson CR, Marzella N.
    Clin Ther; 2010 Aug 23; 32(9):1578-96. PubMed ID: 20974316
    [Abstract] [Full Text] [Related]

  • 8. Achievements in esophagology during 2008.
    Tytgat GN.
    Curr Opin Gastroenterol; 2009 Jul 23; 25(4):339-41. PubMed ID: 19448532
    [No Abstract] [Full Text] [Related]

  • 9. Pantoprazole: a proton pump inhibitor with oral and intravenous formulations.
    Devault KR.
    Expert Rev Gastroenterol Hepatol; 2007 Dec 23; 1(2):197-205. PubMed ID: 19072410
    [Abstract] [Full Text] [Related]

  • 10. Dexlansoprazole MR: a review.
    Hershcovici T, Jha LK, Fass R.
    Ann Med; 2011 Aug 23; 43(5):366-74. PubMed ID: 21366513
    [Abstract] [Full Text] [Related]

  • 11. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
    Hongo M, Miwa H, Kusano M, J-FAST group.
    J Gastroenterol Hepatol; 2012 May 23; 27(5):913-8. PubMed ID: 22142515
    [Abstract] [Full Text] [Related]

  • 12. Pantoprazole available without a prescription: new status. Better than H2 receptor agonists, but not for pregnant women.
    Prescrire Int; 2009 Dec 23; 18(104):250. PubMed ID: 20025090
    [Abstract] [Full Text] [Related]

  • 13. Dexlansoprazole for the treatment of esophagitis and GERD.
    Davies SL.
    Drugs Today (Barc); 2010 Feb 23; 46(2):75-80. PubMed ID: 20393635
    [Abstract] [Full Text] [Related]

  • 14. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
    Abel C, Desilets AR, Willett K.
    Ann Pharmacother; 2010 May 23; 44(5):871-7. PubMed ID: 20371754
    [Abstract] [Full Text] [Related]

  • 15. Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors.
    Miner PB, McKean LA, Gibb RD, Erasala GN, Ramsey DL, McRorie JW.
    Aliment Pharmacol Ther; 2010 Apr 23; 31(8):846-51. PubMed ID: 20146702
    [Abstract] [Full Text] [Related]

  • 16. Evolving issues in the management of reflux disease?
    Yuan Y, Hunt RH.
    Curr Opin Gastroenterol; 2009 Jul 23; 25(4):342-51. PubMed ID: 19417644
    [Abstract] [Full Text] [Related]

  • 17. The impact of lifestyle modification on the health-related quality of life of patients with reflux esophagitis receiving treatment with a proton pump inhibitor.
    Kinoshita Y, Ashida K, Miwa H, Hongo M.
    Am J Gastroenterol; 2009 May 23; 104(5):1106-11. PubMed ID: 19337239
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study.
    Kinoshita Y, Hongo M, Japan TWICE Study Group.
    Am J Gastroenterol; 2012 Apr 23; 107(4):522-30. PubMed ID: 22433921
    [Abstract] [Full Text] [Related]

  • 19. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease.
    Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M.
    J Pediatr; 2009 Apr 23; 154(4):514-520.e4. PubMed ID: 19054529
    [Abstract] [Full Text] [Related]

  • 20. Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year.
    Springer M, Atkinson S, North J, Raanan M.
    Paediatr Drugs; 2008 Apr 23; 10(4):255-63. PubMed ID: 18590344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.